Wedbush Securities
RNAC icon

Wedbush Securities’s Cartesian Therapeutics RNAC Stock Holding History

Wedbush Securities’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$76K Hold
10,500
– – ﹤0.01% 1272
2026
Q2 		$109K Sell
10,500
-1,000
-9% -$7.41K ﹤0.01% 1271
2026
Q1 		$71K Buy
+11,500
New +$81.9K ﹤0.01% 1209

Other funds holding RNAC

Fedenia Advisers
Fedenia Advisers Madison, Wisconsin $425M AUM 89.76% 1-Year Est. Return
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Wedbush Securities's RNAC Position: Q3 2026 in Review

Wedbush Securities held its Cartesian Therapeutics (RNAC) position steady in Q3 2026 at 10,500 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #1272.

Wedbush Securities first reported a position in RNAC in Q1 2026 and has held it in 3 quarters since. The position peaked at $109K in Q2 2026. 13 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Wedbush Securities held 10,500 shares of Cartesian Therapeutics worth $76K as of Q3 2026.
  • Wedbush Securities left its Cartesian Therapeutics share count unchanged in Q3 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Wedbush Securities's portfolio in Q3 2026, its #1272 holding.
  • Wedbush Securities first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Wedbush Securities's Cartesian Therapeutics position peaked at $109K in Q2 2026.
  • 13 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Wedbush Securities's 13F filing for Q3 2026, filed 22 Oct 2026.